New drug aims to tame lupus kidney disease in landmark trial
NCT ID NCT07393451
First seen Feb 06, 2026 · Last updated May 15, 2026 · Updated 19 times
Summary
This study tests a new medicine, SIM0278, in 60 adults with active lupus nephritis, a serious kidney complication of lupus. Participants will receive either SIM0278 or a placebo, along with standard therapy, to see if the drug helps improve kidney function over 52 weeks. The goal is to find a safer and more effective way to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking Union Medical College Hospital
Beijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.